Abstracts

HOW MUTATIONS IN THE HIV-1 3’-POLYPURINE TRACT CONFER DOLUTEGRAVIR RESISTANCE

The integrase strand-transfer inhibitor (INSTI) dolutegravir (DTG) is widely applied in combination antiretroviral therapy for HIV-infected individuals. Resistance to DTG is usually associated with mutations in the integrase gene, but a previous in vitro HIV selection study identified a mutation in the 3′-polypurine tract (3’PPT) that reduced DTG sensitivity (Malet mBio 2017), and mutation of…

HIV DRUG RESISTANCE IN WOMEN RANDOMIZED TO DTG VS EFV OR TDF VS TAF IN PREGNANCY

Virologic failure (VF) and HIV drug resistance (HIVDR) in pregnant and postpartum women with dolutegravir (DTG)-containing antiretroviral treatment (ART) are not well described. We compared VF and HIVDR by study arm in IMPAACT 2010, a randomized trial of 3 ART regimens started in pregnancy (DTG+emtricitabine (FTC)/tenofovir alafenamide (TAF); DTG+FTC/tenofovir disoproxil fumarate (TDF); or efavirenz (EFV)/FTC/TDF.…

EFFICACY OF TENOFOVIR-LAMIVUDINE-DOLUTEGRAVIR FOR INITIAL AND FIRST-LINE SWITCH ART

Single-tablet tenofovir disoproxil fumarate/lamivudine/dolutegravir (TLD) has been rapidly adopted as 1st-line ART for patients initiating treatment and switching from virally-suppressive NNRTI-based 1st regimens in PEPFAR programs. There are limited data, however, on effectiveness and emergence of resistance to TLD in programmatic settings where plasma HIV-1 RNA and drug resistance testing are not used widely. A…

PREDICTORS OF VIRAL SUPPRESSION FOLLOWING ENHANCED ADHERENCE COUNSELING: VISEND TRIAL

The WHO recommends enhanced adherence counseling (EAC) before regimen switch for HIV-positive, antiretroviral therapy (ART)-treated individuals with non-suppressed viral loads (VL). However, there is a paucity of data, especially within a clinical trial setting, on the determinants of viral suppression (VS) following EAC among those failing ART. We thus evaluated predictors of VS among adults…